崔孟超 教授，Prof. Mengchao Cui
先后就读于北京师范大学化学专业本科博士、日本京都大学药学院联合培养博士，现任北京师范大学化学学院/珠海校区文理学院/高等研究院教授。长期聚焦神经退行性疾病与肿瘤的分子影像探针研发，推动多项研究成果实现临床转化。截至目前，已有数十个分子探针通过多家医院伦理委员会审批，相继进入IIT研究，并完成上千例人体显像研究。其中，靶向Aβ的PET诊断药物氟[18F]贝他嗪([18F]Florbetazine)已获国家I类新药临床试验批件，并顺利推进至III期临床阶段，为阿尔茨海默病的早期精准诊断提供了有力工具。已在J. Med. Chem.、Eur. J. Nucl. Med. Mol. I.等期刊发表学术论文120余篇。先后主持重大新药创制子课题、基金委优青项目、联合基金重点项目、面上项目、北京市自科面上项目及北京市科委医药创新品种及平台培育等项目。曾获北京市优秀博士论文奖（2012年）、肖伦青年科技奖（2014年）、华夏医学科技一等奖（2022年）及北京市医学科技一等奖（2024年）。
地址：北京市海淀区新街口外大街19号，北京师范大学化学学院814室，北京100875
邮箱：cmc@bnu.edu.cn
课题组网页：https://www.x-mol.com/groups/Cui_Mengchao
每年招收硕士研究生1名，博士研究生2–3名，并长期招聘博士后研究人员。热忱欢迎对放射性药物、分子影像学感兴趣，有志于从事疾病精准诊断与临床转化研究的同学加入我们！期待您的来信咨询与联系！
研究兴趣和方向
1. 淀粉样蛋白病理靶向分子探针（放射性/荧光）的研制与转化医学研究：聚焦神经退行性疾病（如阿尔茨海默病、帕金森病、肌萎缩侧索硬化）及系统性淀粉样变（如心肌淀粉样变）中的关键病理蛋白，包括Aβ、Tau、α-Synuclein、TDP-43等淀粉样聚集蛋白以及外周器官转甲状腺素蛋白（ATTR）、免疫球蛋白轻链（AL）、降钙素等淀粉样变蛋白，另外还包括其他及中枢神经受体（MAOA/B、TSPO等）。致力于设计、制备并优化兼具高灵敏度与高选择性的新型放射性/荧光分子探针，推动其从基础研究（分子设计合成、放射性核素标记、生物性能评价）到临床转化（伦理审批、人体显像、产品化推进）的全链条发展。
2. 面向精准肿瘤诊疗的创新分子探针开发与转化应用：以前列腺特异性膜抗原（PSMA）、成纤维细胞活化蛋白（FAP）、碳酸酐酶IX（CAIX）等关键肿瘤靶点为核心，致力于研发兼具诊疗一体化功能与多模态成像能力的新型探针（涵盖放射性核素标记、荧光成像及硼中子俘获治疗（BNCT）等策略）。研究覆盖从分子设计、体内行为评价到临床应用（如术中导航、靶向治疗）的完整转化路径。
代表性论文
1. Y. Li; M. Pan; H. Yu; Q. Zhang; Y. Chang; H. Zhao; J. Wang; X. Wang; J. Dai; L. Yu; D. Chen*; J. Zhang; X. Yan; S. Yao*; M. Cui*, Preclinical and preliminary clinical evaluation of [18F]Florbetazine for non-invasive PET detection of cardiac amyloidosis, Eur. J. Nucl. Med. Mol. I., 2026, 53: 3364-3374.
2. X. Wang; M. Wang; Y. Chen; R. Jian; H. Yu; X. Zhang; J. Zhang; S. Yao*; J. Du; M. Cui*, Preclinical evaluation and first-in-human study of 68Ga- and Al18F-Labeled PSMA/FAP bispecific tracers for prostate cancer imaging, Eur. J. Nucl. Med. Mol. I., 2026, 53: 2489-2501.
3. X. Gao; Y. Chen*; Z. Li; X. Zhang; Y. Li; H. Fu; J. Zhang; M. Cui*, Exploring Covalent C–18F Bonding Strategies in the Design of FAP-Targeted Radiotracers, J. Med. Chem., 2026, 69(3): 2938-2953.
4. Y. Chen; X. Zhang*; X. Wang; Y. Liu; J. Zhang*; M. Cui*, Interspecies Variability in Biodistribution and PET Imaging Performance of [18F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer, J. Nucl. Med., 2025, 66: 1271-1277.
5. Q. Wang; J. Song; X. Zhang; Q. Zhang; Y. Li*; X. Yan; J. Dai; J. Zhang; M. Cui*, Rational Design of Pyridinium Styryl Derivatives as PET Tracers for Cardiac Amyloidosis Imaging, J. Med. Chem., 2025, 68(14): 15198-15212.
6. Y. Chen; H. Yu; W. Liu; M. Wang; X. Wang; X. Zhang*; J. Zhang; S. Yao*; M. Cui*, Biphenyl-Trimeric PSMA Theranostic Platform Enables PET Imaging and Optical Detection of Prostate Cancer, J. Med. Chem., 2025, 68(12): 13075-13088.
7. Y. Chen; M. Ni; X. Zhang; X. Wang; K. Wang; Q. Xie*; J. Zhang*; M. Cui*, Preclinical Evaluation and First-in-Human PET Study of Al18F-Labeled Biphenyl-Based Dimeric PSMA Tracers, J. Med. Chem., 2025, 68(6): 6832-6843.
8. Y. Chen; W. Liu; B. Li; X. Gao; K. Zhou; M. Zhang*; G. Yang*; M. Cui*, Synthesis, Preclinical Evaluation, and First-in-Human Assessment of ICG-PSMA-D5: A PSMA-Targeted Probe for Fluorescence-Guided Surgery of Prostate Cancer, J. Med. Chem., 2025, 68(3): 3858-3872.
9. N. Wu; X. Zhang; Y. Li*; J. Zhang*; M. Cui*, Fluorinated Coumarin Derivatives as Selective PET Tracer for MAO-B Imaging, J. Med. Chem., 2025, 68(1): 324-337.
10. X. Wang; X. Zhang; X. Zhang; L. Guan; X. Gao; L. Xu; H. Pang*; J. Du; J. Zhang*; M. Cui*, Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer, Eur. J. Nucl. Med. Mol. I., 2025, 52: 1166-1176.
11. Q. Zeng; X. Zhang; Y. Li*; Q. Zhang; J. Dai; X. Yan; Y. Liu; J. Zhang*; S. Liu; M. Cui*, Discovery and Evaluation of Imidazo[2,1-b][1,3,4]thiadiazole Derivatives as New Candidates for α-Synuclein PET Imaging, J. Med. Chem., 2024, 67(15): 12695-12710.
12. L. Zhang; X. Shi; Y. Li; X. Duan; X. Yang; Z. Hu*; M. Cui*, An NIR-II Probe with High PSMA Affinity Demonstrates an Unexpected Excellent Bone Imaging Ability, J. Med. Chem., 2023, 66, 23, 16441-16454.
13. Y. Chen; X. Zhang; M. Ni; X. Gao; X. Wang; Q. Xie*; J. Zhang*; M. Cui*, Synthesis, Preclinical Evaluation, and First-in-Human PET Study of [68Ga]-Labeled Biphenyl-Containing PSMA Tracers, J. Med. Chem., 2023, 66, 18, 13332-13345.
14. T. Liu; Y. Li; X. Zhang; A. Yao; Y. Wang; S. Yao; B. Chen*; X. Yan; J. Dai; J. Zhang*; M. Cui*, Synthesis and Preclinical Evaluation of 2-(4-[18F]Fluorophenyl)imidazo[1,2-h][1,7]naphthyridine ([18F]FPND-4): An Aza-Fused Tricyclic Derivative as Positron Emission Tomography Tracer for Neurofibrillary Tangle Imaging, J. Med. Chem., 2023, 66, 14, 9561-9576.
15. X. Wang; Y. Chen; Y. Xiong; L. Zhang; B. Wang*; Y. Liu; M. Cui*, Design and Characterization of Squaramic Acid-Based Prostate-Specific Membrane Antigen Inhibitors for Prostate Cancer, J. Med. Chem., 2023, 66, 10, 6889-6904.
16. Y. Li; K. Zhou; X. Zhang; H.g Zhao; X. Wang; R. Dong; Y. Wang; B. Chen; X. Yan; J. Dai; Y. Sui*; J. Zhang*; M. Cui*, Fluorine-18-Labeled Diaryl-azines as Improved β-Amyloid Imaging Tracers: From Bench to First-in-Human Studies, J. Med. Chem., 2023, 66, 7, 4603-4616.
17. T. Xie; Y. Li; C. Tian; C. Yuan; B. Dai; S. Wang; K. Zhou; J. Liu; H. Tan; Y. Liang*; J. Dai; B. Chen*; M. Cui*, Fused Cycloheptatriene–BODIPY Is a High-Performance Near-Infrared Probe to Image Tau Tangles, J. Med. Chem., 2022, 65, 21, 14527-14538.
18. L. Zhang; X. Shi; Y. Li; X. Duan; Z. Zhang; H. Fu; X. Yang; J. Tian; Z. Hu*; M. Cui*, Visualizing Tumors in Real Time: A Highly Sensitive PSMA Probe for NIR-II Imaging and Intraoperative Tumor Resection, J. Med. Chem., 2021, 64, 11, 7735-7745.
19. X. Zhang; Y. Wu; Q. Zeng; T. Xie; S. Yao*; J. Zhang*; M. Cui*, Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion, J. Med. Chem., 2021, 64, 7, 4179-4195.